Clin Surg | Volume 7, Issue 1 | Case Report | Open Access

EML4-ALK (E13:A20) and GPAT3-ALK (G3:A20) Mutations from a Patient with Lung Adenocarcinoma

Tian Tan1, Junfeng Wan3, Hong Wu1, Chenhui Cao1, Yang Liu3, Gang Li2* and Chuan Xu1*

1Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, China
2Department of Thoracic Surgery, Sichuan Provincial People's Hospital, Medicine University of Electronic Science and Technology of China, China
3Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, China

*Correspondance to: Chuan Xu 

Fulltext PDF

Abstract

Background: Anaplastic Lymphoma Kinase (ALK) gene rearrangements appear in 5% to 7% lung adenocarcinoma. With the development of Next-Generation Sequencing (NGS), increasing ALK gene variation (rearrangement/fusion, mutation or amplification) has been discovered. The result of NGS, which could predict the sensitivity of TKI drugs, shows a good correlation with tumor development and therapeutic effect. Case Report: Herein, we report the case of a 49-year-old man who was diagnosed with lung adenocarcinoma and was undergoing ensartinib treatment. The analysis of NGS detected a new ALK fusion combination, namely EML4-ALK and GPAT3-ALK. According to the result of NGS, this patient has higher sensitivity to some TKI drugs. Discussion: Different types of ALK gene mutations are common in lung adenocarcinoma and different degrees of influence on tumors. This case report demonstrates the effectiveness of using NGS to discover novel ALK fusion genes and guide individual therapy.

Citation:

Tan T, Wan J, Wu H, Cao C, Liu Y, Li G, et al. EML4-ALK (E13:A20) and GPAT3- ALK (G3:A20) Mutations from a Patient with Lung Adenocarcinoma. Clin Surg. 2022; 7: 3473..

Subscribe to Our Newsletter